Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RNLX |
---|---|---|
09:32 ET | 348 | 0.4304 |
09:42 ET | 5125 | 0.43 |
09:55 ET | 500 | 0.4395 |
10:06 ET | 3339 | 0.4394 |
10:09 ET | 500 | 0.4394 |
10:22 ET | 6000 | 0.438331 |
10:26 ET | 132 | 0.4394 |
10:31 ET | 246 | 0.4305 |
10:40 ET | 125 | 0.432361 |
11:02 ET | 3258 | 0.446 |
11:03 ET | 300 | 0.44 |
11:05 ET | 2449 | 0.4598 |
11:07 ET | 5600 | 0.4692 |
11:09 ET | 250 | 0.46 |
11:14 ET | 44625 | 0.4598 |
11:25 ET | 3570 | 0.4666 |
11:52 ET | 1000 | 0.45 |
12:10 ET | 100 | 0.45 |
12:19 ET | 1000 | 0.45166 |
12:57 ET | 100 | 0.46 |
01:24 ET | 495 | 0.4559 |
01:36 ET | 800 | 0.4598 |
01:47 ET | 185 | 0.4501 |
01:56 ET | 100 | 0.45 |
02:00 ET | 100 | 0.4501 |
02:03 ET | 189 | 0.4598 |
02:16 ET | 200 | 0.4599 |
02:27 ET | 100 | 0.4502 |
02:56 ET | 648 | 0.459799 |
03:08 ET | 2098 | 0.4504 |
03:19 ET | 4451 | 0.46435 |
03:37 ET | 1980 | 0.4502 |
03:39 ET | 13831 | 0.45 |
03:42 ET | 2670 | 0.45 |
03:46 ET | 1300 | 0.45 |
03:53 ET | 400 | 0.45 |
04:00 ET | 1000 | 0.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Renalytix PLC | 19.6M | -0.4x | --- |
ADM Tronics Unlimited Inc | 6.8M | -12.5x | --- |
Vivos Inc | 19.5M | -7.6x | --- |
Positron Corp | 27.2M | -17.6x | --- |
PAVmed Inc | 23.3M | -0.3x | --- |
Caduceus Software Systems Corp | 15.3M | -47.6x | --- |
Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company. The Company is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Its diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. KidneyIntelX is a bioprognostic methodology. The Company is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations, and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $19.6M |
---|---|
Revenue (TTM) | $2.9M |
Shares Outstanding | 48.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.19 |
EPS | $-1.01 |
Book Value | $0.15 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 6.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,361.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.